Compare RYAN & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYAN | TLX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.6B |
| IPO Year | 2021 | N/A |
| Metric | RYAN | TLX |
|---|---|---|
| Price | $31.86 | $10.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $50.88 | $21.13 |
| AVG Volume (30 Days) | ★ 2.9M | 109.1K |
| Earning Date | 04-30-2026 | 08-19-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $3,051,126,000.00 | N/A |
| Revenue This Year | $15.78 | N/A |
| Revenue Next Year | $12.49 | N/A |
| P/E Ratio | ★ $86.72 | $150.33 |
| Revenue Growth | ★ 21.28 | N/A |
| 52 Week Low | $29.28 | $6.28 |
| 52 Week High | $72.50 | $18.13 |
| Indicator | RYAN | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 52.20 |
| Support Level | $31.50 | $9.46 |
| Resistance Level | $38.61 | $11.28 |
| Average True Range (ATR) | 1.50 | 0.29 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 42.48 | 28.77 |
Ryan Specialty Holdings Inc is an international specialty insurance intermediary providing specialty products, solutions, and services for insurance brokers, agents, and carriers. The company offers wholesale insurance brokerage and delegated underwriting authority products and services, including distribution, underwriting, product development, administration, and risk management. Its expertise spans property, casualty, professional lines, transportation, personal lines, workers compensation, and employee benefits insurance, across traditional insurance and alternative risk solutions. The company operates in the United States and foreign markets, with the majority of revenue generated from the United States.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.